Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background: The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer’s disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [18 F]GTP1 tau PET and subsequent longitudinal change across multiple cognitive measures over 18 months. Methods: Our analyses incorporated data from 67 participants, including cognitively normal controls (n = 10) and β-amyloid (Aβ)-positive individuals ([18 F] florbetapir Aβ PET) with prodromal (n = 26), mild (n = 16), or moderate (n = 15) AD. Baseline measurements included cortical volume (MRI), tau burden ([18 F]GTP1 tau PET), and cognitive assessments [Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), 13-item version of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)]. Cognitive assessments were repeated at 6-month intervals over an 18-month period. Associations between baseline [18 F]GTP1 tau PET indices and longitudinal cognitive performance were assessed via univariate (Spearman correlations) and multivariate (linear mixed effects models) approaches. The utility of potential prognostic tau PET cut points was assessed with ROC curves. Results: Univariate analyses indicated that greater baseline [18 F]GTP1 tau PET signal was associated with faster rates of subsequent decline on the MMSE, CDR, and ADAS-Cog13 across regions of interest (ROIs). In multivariate analyses adjusted for baseline age, cognitive performance, cortical volume, and Aβ PET SUVR, the prognostic performance of [18 F]GTP1 SUVR was most robust in the whole cortical gray ROI. When AD participants were dichotomized into low versus high tau subgroups based on baseline [18 F]GTP1 PET standardized uptake value ratios (SUVR) in the temporal (cutoff = 1.325) or whole cortical gray (cutoff = 1.245) ROIs, high tau subgroups demonstrated significantly more decline on the MMSE, CDR, and ADAS-Cog13. Conclusions: Our results suggest that [18 F]GTP1 tau PET represents a prognostic biomarker in AD and are consistent with data from other tau PET tracers. Tau PET imaging may have utility for identifying AD patients at risk for more rapid cognitive decline and for stratification and/or enrichment of participant selection in AD clinical trials. Trial registration ClinicalTrials.gov NCT02640092. Registered on December 28, 2015
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519 · cited 1×
“Neuropsychological testing Cognitive assessments at baseline and 6-, 12-, and 18-month post-baseline visits included the MMSE, CDR, 13-item version of the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) [33], and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [34].”
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · cited 2×
“Composite ROIs included whole cortical gray matter (WCG), an AD-signature temporal ROI [20], and hierarchical in vivo Braak (I/II, III/ IV, V/VI) [29, 30] that correspond to neuropathological NFT staging [31].”
Self-citationTau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., Cosio, D. M. O., Farrell, M., Quiroz, Y. T., Mormino, E. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1424 · Cited by 865
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628 · cited 6×
“Tau PET imaging, particularly with second-generation tracers that exhibit less off-target binding [4], may represent an informative biomarker for tau pathology in AD, as evidenced by its inclusion in the National Institute on Aging-Alzheimer’s Association (NIA-AA) Research Framework for biological diagnosis of AD [7]…”
InfluentialOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311 · cited 2×
“These results are consistent with previous studies supporting the prognostic potential of other tau PET tracers, including [18F]flortaucipir [10–13, 17], [18F]MK-6240 [15], and [18F]RO948 [17].”
Self-citation
Cited by
Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02049-x · Cited by 496
Self-citationExplainable Artificial Intelligence in Neuroimaging of Alzheimer’s Disease
Taiyeb Khosroshahi, M., Morsali, S., Gharakhanlou, S., Motamedi, A., Hassanbaghlou, S., Vahedi, H., Pedrammehr, S., Kabir, H. M. D., & Jafarizadeh, A. (2025) · Diagnostics · doi:10.3390/diagnostics15050612 · Cited by 68
“Studies have demonstrated that FDG-PET can accurately distinguish between AD patients and healthy controls and differentiate between various stages of the disease [50,51].”
Tau; One Protein, So Many Diseases
Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33
“Additionally, [18F] GTP1, [18F] flortaucipir, [18F]MK-6240, and [18F]RO948 tau-PET have been studied as other tau tracers [82].”
Methodvan Dyck, C. H., Mecca, A. P., O’Dell, R. S., Bartlett, H. H., Diepenbrock, N. G., Huang, Y., Hamby, M. E., Grundman, M., Catalano, S. M., Caggiano, A. O., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01382-2 · Cited by 29
Metadata
- Authors
- Teng, E., Manser, P. T., Sanabria Bohorquez, S., Wildsmith, K. R., Pickthorn, K., Baker, S. L., Ward, M., Kerchner, G. A., & Weimer, R. M.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2021-12-01
- Volume
- 13
- Issue
- 1
- Pages
- 196-196
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W3214825295
- Cited by
- 30
- References
- 16
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-021-00937-x
- The paper
- Teng, E., Manser, P. T., Sanabria Bohorquez, S., Wildsmith, K. R., Pickthorn, K., Baker, S. L., Ward, M., Kerchner, G. A., & Weimer, R. M. (2021). Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-021-00937-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.